Cochlear Limited provides implantable hearing solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers cochlear implants, including Nucleus 7 and Kanso sound processors; Carina middle-ear implants and accessories; and Baha bone conduction implants, such as Baha attract system, Baha connect system, Baha softband, Baha 5 sound processor, Baha 5 power, Baha 5 superpower, other sound processors, and wireless accessories. It also provides Cochlear true wireless devices comprising mini microphones, phone clips, and TV streamers; and Cochlear Vistafix bone-anchored facial prosthetic solutions to enhance the attachment and cosmetic outcome of facial prostheses. The company has strategic collaborations with Sensorion and GN Hearing A/S to focus on improving hearing outcomes in patients with cochlear implants. Cochlear Limited was incorporated in 1983 and is headquartered in Sydney, Australia.
Industry, Sector and Symbol
Industry Medical Devices
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+61-2-94286555
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.42 billion
Profitability
Miscellaneous
Employees3,500
Next Earnings DateN/A
OptionableOptionable
Cochlear (ASX:COH) Frequently Asked Questions
What is Cochlear's stock symbol?
Cochlear trades on the ASX under the ticker symbol "COH."
How often does Cochlear pay dividends? What is the dividend yield for Cochlear?
Cochlear announced a Interim dividend on Wednesday, February 20th. Shareholders of record on Tuesday, April 16th will be given a dividend of 1.55 per share on Tuesday, April 16th. This represents a yield of 0.89%. The ex-dividend date of this dividend is Monday, March 25th. View Cochlear's Dividend History.
What price target have analysts set for COH?
3 Wall Street analysts have issued 1-year price targets for Cochlear's shares. Their predictions range from A$53.00 to A$53.00. On average, they anticipate Cochlear's share price to reach A$53.00 in the next year. This suggests that the stock has a possible downside of 70.2%. View Analyst Price Targets for Cochlear.
What is the consensus analysts' recommendation for Cochlear?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cochlear in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cochlear.
Has Cochlear been receiving favorable news coverage?
Media headlines about COH stock have been trending somewhat negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cochlear earned a news impact score of -1.1 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days.
Who are some of Cochlear's key competitors?
Some companies that are related to Cochlear include Fisher & Paykel Healthcare (FPH), ConvaTec Group (CTEC), Inspire Medical Systems (INSP), Draegerwerk AG & Co KGaA (DRW3), Stratec Biomedical (SBS), Avita Medical (AVH), Helius Medical Technologies (HSM), Creo Medical Group (CREO), Medica Group (MGP), Hamilton Thorne (HTL), Titan Medical (TMD), Kromek Group (KMK), Cyclopharm (CYC), Impedimed (IPD) and Advanced Oncotherapy (AVO).
What other stocks do shareholders of Cochlear own?
Who are Cochlear's key executives?
Cochlear's management team includes the folowing people:
- Mr. Diggory William Howitt, CEO, MD, Pres & Exec. Director (Age 52)
- Mr. Brent Andrew Cubis, Chief Financial Officer
- Mr. Jan Janssen, Chief Technology Officer
- Mr. Richard Brook, Pres of EMEA & Latin American Region
- Mr. Anthony Manna, Pres of Americas Region
What is Cochlear's stock price today?
One share of COH stock can currently be purchased for approximately A$177.94.
How big of a company is Cochlear?
Cochlear has a market capitalization of $10.27 billion and generates $1.42 billion in revenue each year. Cochlear employs 3,500 workers across the globe.
What is Cochlear's official website?
How can I contact Cochlear?
Cochlear's mailing address is 1 University Avenue Macquarie University, SYDNEY, NSW 2109, Australia. The company can be reached via phone at +61-2-94286555.
MarketBeat Community Rating for Cochlear (ASX COH)
MarketBeat's community ratings are surveys of what our community members think about Cochlear and other stocks. Vote "Outperform" if you believe COH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COH will underperform the S&P 500 over the long term. You may vote once every thirty days.
